Acorda Therapeutics announced the U.S. Food and Drug Administration (FDA) approved INBRIJA for intermittent treatment of OFF episodes in people with Parkinson’s disease treated with carbidopa/levodopa.....
Acorda Therapeutics reported Thursday that the FDA extended its review of a filing seeking clearance of Inbrija (levodopa) by three months to January 5, 2019.
Rumors that Acorda Therapeutics was considering a sale drove company stock up about 12 percent on Friday, Jan. 5, to hit $23.55. The Wall Street Journal reported that Acorda had brought in advisers to assist in exploring an auction.